A molecular signature for the prediction of recurrence in colorectal cancer.
A molecular signature for the prediction of recurrence in colorectal cancer.
复制标题
DOI：
10.1186/s12943-015-0296-2
复制
发表时间：
2015-02-03
期刊：
影响因子：
37.3
通讯作者：
Du X
中科院分区：
文献类型：
--
作者：
Wang L;Shen X;Wang Z;Xiao X;Wei P;Wang Q;Ren F;Wang Y;Liu Z;Sheng W;Huang W;Zhou X;Du X
一些临床和病理因素对结直肠癌(CRC)的预后有影响，但它们还不足以进行风险评估。我们的目标是确定一种分子标记，能够可靠地识别复发风险较高的CRC患者。本研究共收集281份儿童肿瘤样本(第二/第三阶段)。进行了两步基因表达谱研究。首先，使用Affymetrix Human Genome U133 Plus 2.0阵列获得了81个新鲜冷冻结直肠癌样本的基因表达谱。其次，使用200个新鲜冰冻样本和Taqman低密度阵列(TLDA)分析，进行了集中的基因表达分析，包括预后基因和文献综述中感兴趣的基因。应用Logistic回归分析建立了预测II/III期结直肠癌复发的最优31基因表达分类器。这一基因表达特征将58.5%的患者归类为低风险患者，41.5%归类为高危患者(P <； 0.001)。在多变量分析中，信号是最强的独立预后因素。低危组和高危组的5年无复发生存率分别为88.5%和41.3%(P <； 0.001)。我们确定了一个与II/III期CRC患者的临床结果密切相关的31个基因表达特征。
Several clinical and pathological factors have an impact on the prognosis of colorectal cancer (CRC), but they are not yet adequate for risk assessment. We aimed to identify a molecular signature that can reliably identify CRC patients at high risk for recurrence. Two hundred eighty-one CRC samples (stage II/III) were included in this study. A two-step gene expression profiling study was conducted. First, gene expression measurements from 81 fresh frozen CRC samples were obtained using Affymetrix Human Genome U133 Plus 2.0 Arrays. Second, a focused gene expression assay, including prognostic genes and genes of interest from literature reviews, was performed using 200 fresh frozen samples and a Taqman low-density array (TLDA) analysis. An optimal 31-gene expression classifier for the prediction of recurrence among patients with stage II/III CRC was developed using logistic regression analysis. This gene expression signature classified 58.5% of patients as low-risk and 41.5% as high-risk (P < 0.001). The signature was the strongest independent prognostic factor in the multivariate analysis. The five-year relapse-free survival (RFS) rates for the low-risk patients and the high-risk patients were 88.5% and 41.3% (P < 0.001), respectively. We identified a 31-gene expression signature that is closely associated with the clinical outcome of stage II/III CRC patients.
登录
查看更多内容
影响因子：
24.5
作者：
Pritchard CC;Grady WM
通讯作者：
Grady WM
DOI：
10.1158/1078-0432.ccr-11-2483
发表时间：
2012-04-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Garcia I;Mayol G;Ríos J;Domenech G;Cheung NK;Oberthuer A;Fischer M;Maris JM;Brodeur GM;Hero B;Rodríguez E;Suñol M;Galvan P;de Torres C;Mora J;Lavarino C
通讯作者：
Lavarino C
影响因子：
24.5
作者：
Hur K;Toiyama Y;Takahashi M;Balaguer F;Nagasaka T;Koike J;Hemmi H;Koi M;Boland CR;Goel A
通讯作者：
Goel A
影响因子：
6.4
作者：
Hilska, Marja;Roberts, Peter J.;Laato, Matti
通讯作者：
Laato, Matti
影响因子：
7.5
作者：
Haffner, Michael C.;Laimer, Johannes;Bander, Neil H.
通讯作者：
Bander, Neil H.